American Society of Hirudotherapy

An optimized method to assess in vivo efficacy of antithrombotic drugs using optical coherence tomography and a modified Doppler flow system

Research article published in Journal of pharmacological and toxicological methods (2011)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Drug DevelopmentCouture L et al. · Journal of pharmacological and toxicological methods, 2011

Abstract

INTRODUCTION: Animal models of venous and arterial thrombosis are extremely useful to study the efficacy of antithrombotic agents. Variability in efficacy data is often observed in those preclinical studies. The goal of this study was to optimize the methodology for assessing antithrombotic drug efficacy by the use of optical coherence tomography (OCT) and a modified Doppler flow system in rat models of thrombosis. METHODS: Thrombus formation was assessed in both the rat venous and arterial ferric chloride (FeCl(3)) models of thrombosis. In the venous model, thrombus volume post-treatment was measured using OCT, and data were correlated against the thrombus weight. In the arterial model, the time to occlusion was measured using a Doppler flow probe connected to a perivascular flow module which allowed the reporting of dynamic blood flow data every 30s. Heparin (130 or 165U/kg), argatroban (4.5mg/kg), bivalirudin (1.3mg/kg) or saline were administered intravenously. RESULTS: In the venous model, for all treatment groups a strong linear correlation (R(2)=0.998) was observed between thrombus volume measured by OCT and thrombus weight. In the arterial model, using a high sampling rate of a dynamic blood flow using a modified Doppler flow system provided data accuracy and precision of the time to occlusion measurement. DISCUSSION: This study demonstrates that OCT is a powerful tool for the assessment of antithrombotic drug efficacy. Furthermore, it shows that a high Doppler sampling rates of dynamic blood flow leads to data accuracy and precision.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsArginineDrug Evaluation, PreclinicalFibrinolytic AgentsHeparinHirudinsLaser-Doppler FlowmetryMalePeptide FragmentsPipecolic AcidsRatsRats, Sprague-Dawley

Summary

Animal models of venous and arterial thrombosis are extremely useful to study the efficacy of antithrombotic agents.

Why This Matters for Hirudotherapy

This methodological study optimized assessment of antithrombotic drug efficacy using optical coherence tomography (OCT) and a modified Doppler flow system in rat FeCl₃-induced venous and arterial thrombosis models. Heparin, argatroban, bivalirudin, or saline were administered intravenously as test treatments; a strong linear correlation (R²=0.998) between OCT-measured thrombus volume and thrombus weight was demonstrated in the venous model, and the modified Doppler system provided accurate and precise time-to-occlusion measurement in the arterial model. No defensible leech or hirudotherapy link exists in this abstract: bivalirudin is listed among test drugs but the abstract provides no characterization connecting it to hirudin or leeches. The study's purpose is imaging methodology validation for preclinical antithrombotic assessment.

Citation

An optimized method to assess in vivo efficacy of antithrombotic drugs using optical coherence tomography and a modified Doppler flow system

Couture L et al. · Journal of pharmacological and toxicological methods, 2011

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.